FerInject

Brief title: FerInject
Design: Intravenöse Eisencarboxymaltose versus orale Eisensubstitution bei
Patienten mit metastasiertem kolorektalem Karzinom (CRC) und
Eisenmangelanämie: eine randomisierte, multizentrische
Therapieoptimierungsstudie (FerInject)
No of patients: 64
Status: Under preparation

Brief title: Nepafox
Design: A randomized, multicentre phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in patients with resectable pancreatic cancer.
No of patients: 126 (phase II)
Status: Under preparation

Double blind phase II/III study to determine the overal survival as the primary endpoint. Secondary endpoints are the progression free survival and the mortality/morbidity.

In der vorliegende randomisierten, explorativen Phase II-Studie wird derals primärer Endpunkt der Anstieg des Serum Hämoglobins um 2g/dl oder Normalisiernug (12g/dl) des Serum Hämoglobins untersucht. Sekundäre Endpunkte sind u.a.Verträglichkeit und Toxizität und Erfassung der Lebensqualität.

LKP:
Prof. Dr. S.E. Al-Batran
Institut für Klinisch-Onkologische Forschung
Krankenhaus Nordwest GmbH
Steinbacher Hohl 2-26
60488 Frankfurt/Main

CabaGast

Brief title: CabaGast
Design: Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach
No of patients: 65
Status: Rekrutiierung beendet

Single-arm study to determine response rate in second-line treatment with cabazitaxel after the failure of palliative primary treatment.

LKP:
Dr. H. Schmalenberg
Universitätsklinikum Jena
Bachstr. 18
07743 Jena

More information

RadPAC

Brief title: RADPAC
Design: A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen
No of patients: 480
Status: Recruiting

This is a randomized, double-blind, phase III two-arm multi-center study aiming at estimating the relative efficacy of the combination of RAD001 and paclitaxel versus that of paclitaxel alone in terms of hazard ratio of overall survival in patients with gastric cancer who have relapsed after one treatment regimen containing a fluoropyrimidine. Primary endpoint is the overall survival, secondary endpoints are treatment efficacy in terms of best overall response, disease control rate and progression free survival and AEs/SAEs, discontinuation rate, dose adjustment rate and tolerability.
 

LKP:
Prof. Dr. S.E. Al-Batran
Institut für Klinisch-Onkologische Forschung
Krankenhaus Nordwest GmbH
Steinbacher Hohl 2-26
60488 Frankfurt/Main
 

More information